Guggenheim Downgrades Sage Therapeutics (SAGE) to Neutral, Following Clinical Business Update
Tweet Send to a Friend
Guggenheim analyst Yatin Suneja downgraded Sage Therapeutics (NASDAQ: SAGE) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
